DÉRIVÉS DE BRIGATINIB MODIFIÉS PAR DEUTÉRIUM, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET UTILISATION CORRESPONDANTE

• 收藏
• 分享

专利权人:

Ltd.;Chai Tai Tianqing Pharmaceutical Group Co.

发明人:

ZHANG, Yinsheng,LIU, Baomin,YANG, Beibei

申请号：

EP16868007

公开号：

EP3381925A4

申请日:

2016.11.24

申请国别(地区):

EP

年份:

2018

代理人:

摘要：

The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/